These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 17912451

  • 1. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.
    Sotomayor S, Carmena MJ, Schally AV, Varga JL, Sánchez-Chapado M, Prieto JC, Bajo AM.
    Int J Oncol; 2007 Nov; 31(5):1223-30. PubMed ID: 17912451
    [Abstract] [Full Text] [Related]

  • 2. Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells.
    Valdehita A, Bajo AM, Schally AV, Varga JL, Carmena MJ, Prieto JC.
    Mol Cell Endocrinol; 2009 Apr 10; 302(1):41-8. PubMed ID: 19101605
    [Abstract] [Full Text] [Related]

  • 3. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
    Rekasi Z, Schally AV, Plonowski A, Czompoly T, Csernus B, Varga JL.
    Prostate; 2001 Aug 01; 48(3):188-99. PubMed ID: 11494334
    [Abstract] [Full Text] [Related]

  • 4. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
    Xie Y, Wolff DW, Lin MF, Tu Y.
    Mol Pharmacol; 2007 Jul 01; 72(1):73-85. PubMed ID: 17430995
    [Abstract] [Full Text] [Related]

  • 5. Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-kappaB in human prostate cell lines Differential time-dependent responses in cancer progression.
    Fernández-Martínez AB, Collado B, Bajo AM, Sánchez-Chapado M, Prieto JC, Carmena MJ.
    Mol Cell Endocrinol; 2007 May 30; 270(1-2):8-16. PubMed ID: 17434257
    [Abstract] [Full Text] [Related]

  • 6. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
    Lyne JC, Melhem MF, Finley GG, Wen D, Liu N, Deng DH, Salup R.
    Cancer J Sci Am; 1997 May 30; 3(1):21-30. PubMed ID: 9072304
    [Abstract] [Full Text] [Related]

  • 7. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells.
    Fernández-Martínez AB, Bajo AM, Sánchez-Chapado M, Prieto JC, Carmena MJ.
    Prostate; 2009 May 15; 69(7):774-86. PubMed ID: 19189304
    [Abstract] [Full Text] [Related]

  • 8. Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K.
    Gutiérrez-Cañas I, Juarranz MG, Collado B, Rodríguez-Henche N, Chiloeches A, Prieto JC, Carmena MJ.
    Prostate; 2005 Apr 01; 63(1):44-55. PubMed ID: 15468165
    [Abstract] [Full Text] [Related]

  • 9. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers.
    Rekasi Z, Varga JL, Schally AV, Halmos G, Armatis P, Groot K, Czompoly T.
    Endocrinology; 2000 Jun 01; 141(6):2120-8. PubMed ID: 10830299
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity.
    Plonowski A, Varga JL, Schally AV, Krupa M, Groot K, Halmos G.
    Int J Cancer; 2002 Apr 01; 98(4):624-9. PubMed ID: 11920625
    [Abstract] [Full Text] [Related]

  • 11. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A, Schally AV, Varga JL, Hammann BD, Groot K, Halmos G, Cai RZ, Zarandi M.
    Prostate; 2005 Aug 01; 64(3):303-15. PubMed ID: 15754342
    [Abstract] [Full Text] [Related]

  • 12. Hypoxia regulation of expression and angiogenic effects of vasoactive intestinal peptide (VIP) and VIP receptors in LNCaP prostate cancer cells.
    Collado B, Sánchez-Chapado M, Prieto JC, Carmena MJ.
    Mol Cell Endocrinol; 2006 Apr 25; 249(1-2):116-22. PubMed ID: 16563610
    [Abstract] [Full Text] [Related]

  • 13. Multifunctional role of VIP in prostate cancer progression in a xenograft model: suppression by curcumin and COX-2 inhibitor NS-398.
    Fernández-Martínez AB, Bajo AM, Valdehita A, Isabel Arenas M, Sánchez-Chapado M, Carmena MJ, Prieto JC.
    Peptides; 2009 Dec 25; 30(12):2357-64. PubMed ID: 19772879
    [Abstract] [Full Text] [Related]

  • 14. Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog.
    Collado B, Carmena MJ, Sánchez-Chapado M, Ruíz-Villaespesa A, Bajo AM, Fernández-Martínez AB, Varga JL, Schally AV, Prieto JC.
    Int J Oncol; 2005 Jun 25; 26(6):1629-35. PubMed ID: 15870879
    [Abstract] [Full Text] [Related]

  • 15. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
    Jiang S, Kopras E, McMichael M, Bell RH, Ulrich CD.
    Cancer Res; 1997 Apr 15; 57(8):1475-80. PubMed ID: 9108448
    [Abstract] [Full Text] [Related]

  • 16. Study of species specificity in growth hormone-releasing factor (GRF) interaction with vasoactive intestinal peptide (VIP) receptors using GRF and intestinal VIP receptors from rat and human: evidence that Ac-Tyr1hGRF is a competitive VIP antagonist in the rat.
    Laburthe M, Couvineau A, Rouyer-Fessard C.
    Mol Pharmacol; 1986 Jan 15; 29(1):23-7. PubMed ID: 3003561
    [Abstract] [Full Text] [Related]

  • 17. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.
    Nagasawa J, Mizokami A, Koshida K, Yoshida S, Naito K, Namiki M.
    Int J Urol; 2006 May 15; 13(5):587-92. PubMed ID: 16771730
    [Abstract] [Full Text] [Related]

  • 18. Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells.
    Valdehita A, Carmena MJ, Collado B, Prieto JC, Bajo AM.
    Regul Pept; 2007 Dec 04; 144(1-3):101-8. PubMed ID: 17683807
    [Abstract] [Full Text] [Related]

  • 19. Regulation of cyclooxygenase-2 pathway by HER2 receptor.
    Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J, Kumar R.
    Oncogene; 1999 Jan 14; 18(2):305-14. PubMed ID: 9927187
    [Abstract] [Full Text] [Related]

  • 20. RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells.
    Valdehita A, Carmena MJ, Bajo AM, Prieto JC.
    Mol Cell Endocrinol; 2012 Jan 02; 348(1):241-6. PubMed ID: 21896307
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.